The Journal of Clinical Psychiatry

Author Index to Volume 67: January 2006 Through December 2006

Abi-Saab W see Bowden CL
Adams BE see Frye MA
Adams DH see Brown EB; Ketter TA
Addington DEN, Pantelis C, Loebel AD, Romano SJ. Reply to Gharabawi GM: Methodological issues in a comparative study of ziprasidone and risperidone [letter]. Jan 163–164
Adetunji B, Basil B, Mathews M, Williams A, Osinowo T. Methodological issues in a study of long-term maintenance therapy with quetiapine versus haloperidol decanoate [letter with reply]. Mar 497
Adler CM see Weinstein SK
Adler LA see Spencer TJ
Adult ADHD Research Group see Weiss M
Agerbo E see Qin P
Ahearn EP see Deneys ML
Ahl J see Houston JP
Ahn YM see Chang JS
Akdede BBK, Yağcıoğlu AEA, Alptekin K, Turgut TI, Tümüklü M, Yazıcı MK, Jayathilake K, Tunca Z, Göğüş A, Meltzer HY. Double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Dec 1912–1919
Akyuz G see Sar V
Albanese MJ see Manwani SG
Albert MJ see Tondo L
Alda M see McGirr A
Aleardi M see Biederman J; Fried R
Alegria M, Canino G, Stinson FS, Grant BF. Nativity and DSM-IV psychiatric disorders among Puerto Ricans, Cuban Americans, and non-Latino whites in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Jan 56–65
Alessi-Severini S, Honcharik PL, Simpson KD, Eleff MK, Collins DM. Evaluation of an interchangeability switch in patients treated with clozapine: a retrospective review. July 1047–1054
Allen A see Dell'Osso B; Wainberg ML
Allen J see Dunner DL
Allen JJB, Schnyer RN, Chambers AS, Hitt SK, Moreno FA, Manber R. Acupuncture for depression: a randomized controlled trial. Nov 1665–1673
Allen MH see Bauer MS
Allison KC see Stunkard AJ
Almeida OP, Waterreus A, Hankey GJ. Preventing depression after stroke: results from a randomized placebo-controlled trial. July 1104–1109
Alpert JE see Fava M; Pilowsky DJ
Alptekin K see Akdede BBK
Altshuler LL, Post RM, Black DO, Keck PE Jr, Nolen WA, Frye MA, Suppes T, Grunze H, Kupka RW, Leverich GS, McElroy SL, Walden J, Mintz J. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. Oct 1551–1560
Álvarez-Jiménez M, González-Blanch C, Vázquez-Barquero JL, Pérez-Iglesias R, Martínez-García O, Pérez-Pardal T, Ramírez-Bonilla ML, Crespo-Facorro B. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. Aug 1253–1260
Aman MG. Reply to Slaff I: Response to the management of autism and its related disorders [letter]. Dec 2031–2032
Amann B see Sterr A
Amital D, Vishne T, Roitman S, Kotler M, Levine J. Open study of creatine monohydrate in treatment-resistant posttraumatic stress disorder [letter]. May 836–837
Anand S see Chand PK
Andersen HF see Bandelow B
Andrade C, Singh NM, Bhakta SG. Simultaneous true seizures and pseudoseizures [letter]. Apr 673
Andreassen OA see Birkenaes AB
Andreoli A see Damsa C
Anghelescu I see Bajbouj M; Wolf J
Anolik R see Mago R
Appleby L see Kapur N
Arana-Lechuga Y see Prospero-Garcia KA
Argiriou S see Zink M
Aripiprazole Study Group see Keck PE Jr
Arlien-Soborg P see Kondziella D
Armistead MS see Nierenberg AA
Arnold LM, Hudson JI, Keck PE Jr, Auchenbach MB, Javaras KN, Hess EV. Comorbidity of fibromyalgia and psychiatric disorders. Aug 1219–1225
Arnsten AFT. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. Suppl 8, 7–12
Artés-Rodríguez A see Baca-García E
Arvilommi P see Mantere O
Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. Mar 453–460
Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR. Prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. July 1114–1123
ASCP Examination Committee. ASCP administers 10th certification exam [ASCP Corner]. July 1152–1153
Atbasoglu EC see Senturk V
Attiullah N see Zimmerman M
Auchenbach MB see Arnold LM
Aukst-Margetic B, Margetic B. Monosymptomatic hypochondriacal psychosis or tardive dystonia? [letter with reply] Feb 328–329
Aupperle PM. Navigating patients and caregivers through the course of Alzheimer's disease. Suppl 3, 8–14
Austin C see Ninan PT
Baca-García E, Oquendo MA, Saiz-Ruiz J, Mann JJ, de Leon J. Pilot study on differences in aggression in New York City and Madrid, Spain, and their possible impact on suicidal behavior. Mar 375–380
Baca-García E, Perez-Rodriguez MM, Basurte-Villamor I, Saiz-Ruiz J, Leiva-Murillo JM, de Prado-Cumplido M, Santiago-Mozos R, Artés-Rodríguez A, de Leon J. Using data mining to explore complex clinical decisions: a study of hospitalization after a suicide attempt. July 1124–1132
Bacalman S, Farzin F, Bourgeois JA, Cogswell J, Goodlin-Jones BL, Gane LW, Grigsby J, Leehey MA, Tassone F, Hagerman RJ. Psychiatric phenotype of the fragile X–associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. Jan 87–94
Bácskai E see Gerevich J
Badgett KS see Clancy CP
Baer L, Minichiello WE. Internet assessment of obsessive-compulsive disorder [letter]. Sept 1473
Bahk W-M see Kwon JS
Bajbouj M, Danker-Hopfe H, Heuser I, Anghelescu I. Long-term outcome of vagus nerve stimulation in rapid-cycling bipolar disorder [letter]. May 837–838
Baker RW see Perlis RH
Bakim B see Karamustafalioglu OK
Baldassano CF. Illness course, comorbidity, gender, and suicidality in patients with bipolar disorder. Suppl 11, 8–11
Baldassano CF see Joffe H
Baldessarini RJ see Houston JP; Tondo L
Baldwin DS, Papakostas GI. Symptoms of fatigue and sleepiness in major depressive disorder. Suppl 6, 9–15
Baldwin DS see Bandelow B; Nutt DJ; Stein DJ; Williams VSL
Ball JR, Mitchell PB, Corry JC, Skillecorn A, Smith M, Malhi GS. Randomized controlled trial of cognitive therapy for bipolar disorder: focus on long-term change. Feb 277–286

Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. Apr 554–566
Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? Sept 1428–1434
Bandelow B see Stein DJ
Barbui C, Cipriani A, Malvini L, Tansella M. Validity of the impact factor of journals as a measure of randomized controlled trial quality. Jan 37–40
Barbui C see Cipriani A
Barnhill LJ see Janowsky DS
Bartoli L see Maj M
Bascaran M-T see De la Fuente JM
Basil B see Adetunji B
Basurte-Villamor I see Baca-García E
Bauer MS. Reply to Benazzi F: Mixed depression, suicidality, and antidepressants [letter]. Oct 1650–1651
Bauer MS, Wisniewski SR, Marangell LB, Chessick CA, Allen MH, Dennehy EB, Miklowitz DJ, Thase ME, Sachs GS, for the STEP-BD Investigators. Are antidepressants associated with new-onset suicidality in bipolar disorder? a prospective study of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Jan 48–55
Bäuml J see Pitschel-Walz G
Baxi L see Neugebauer R
Beach TG see Caselli RJ
Beauregard M see Mancini-Marïe A
Beckham JC see Clancy CP
Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. July 1042–1046
Benabarre A see Plana MT
Benattia I see Kroenke K
Benazzi F. Atypical depression: category or specifier? [letter with reply] June 996–997
Benazzi F. Mixed depression, suicidality, and antidepressants [letter with reply]. Oct 1650–1651
Benazzi F see Fava M
Bender W see Pitschel-Walz G
Benkelfat C see McGirr A
Ben-Menachem E see Merrill CA
Berg PH see Cavazzoni PA
Bergbauer G see Steinert T
Berman SR see Trivedi MH
Berner MM, Hagen M, Kriston L. Systematic review of research on strategies for the management of antipsychotic-induced sexual dysfunction: high-level evidence is needed [letter]. Oct 1649–1650
Bernet W. Review of Scott CL, Gerbasi JB (eds): *Handbook of Correctional Mental Health.* Aug 1312–1313
Bernstein MB see Hasan AM
Bhakta SG see Andrade C
Bhat SK. Baron and the medical student [A Psychiatrist's Diary]. July 1154–1155
Bhat SK. Busman's holiday [A Psychiatrist's Diary]. June 993–994
Bhat SK. Contagion [A Psychiatrist's Diary]. Dec 2028–2029
Bhat SK. Days like this [A Psychiatrist's Diary]. Sept 1468–1469
Bhat SK. Death of a Buddha [A Psychiatrist's Diary]. Oct 1647–1648
Bhat SK. No further history [A Psychiatrist's Diary]. May 833–834
Bhat SK. Until death do us part [A Psychiatrist's Diary]. Nov 1815–1816
Bhui K, Rüdell K, Priebe S. Assessing explanatory models for common mental disorders. June 964–971
Biederman J. Introduction: new developments in the treatment of attention-deficit/hyperactivity disorder. Suppl 8, 3–6
Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. Apr 524–540
Biederman J, Petty CR, Faraone SV, Hirshfeld-Becker DR, Henin A, Brauer L, Kaufman B, Rosenbaum JF. Antecedents to panic disorder in nonreferred adults. Aug 1179–1186
Biederman J, Swanson JM, Wigal SB, Boellner SW, Earl CQ, Lopez FA, for the Modafinil ADHD Study Group. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study. May 727–735
Biederman J see Fried R; Spencer TJ; Surman CBH; Swanson JM; Wilens TE
Bilgic A see Senturk V
Bird SA see Ernst CL
Birkenaes AB, Søgaard AJ, Engh JA, Jonsdottir H, Ringen PA, Vaskinn A, Friis S, Sundet K, Opjordsmoen S, Andreassen OA. Sociodemographic characteristics and cardiovascular risk factors in patients with severe mental disorders compared with the general population. Mar 425–433
Birkenhäger TK, van den Broek WW, Moleman P, Bruijn JA. Outcome of a 4-step treatment algorithm for depressed inpatients. Aug 1266–1271
Birkenhäger TK see van den Broek WW
Bjelland I see Raeder MB
Black DO see Altshuler LL
Blacker D see Finn CT
Blanch J see Plana MT
Blanco C, Olfson M, Stein DJ, Simpson HB, Gameroff MJ, Narrow WH. Treatment of obsessive-compulsive disorder by US psychiatrists. June 946–951
Blanco C see Lewis-Fernández R
Blank S, Lenze EJ, Mulsant BH, Dew MA, Karp JF, Shear MK, Houck PR, Miller MD, Pollock BG, Tracey B, Reynolds CF III. Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment. Mar 468–472
Bleiberg KL see Neugebauer R
Bleich S see Hillemacher T
Blennow K see Merrill CA
Blier P, Tremblay P. Physiologic mechanisms underlying the antidepressant discontinuation syndrome. Suppl 4, 8–13
Blier P see Schatzberg AF
Block JJ. Use of a TENS unit to treat self-cutting in a patient with borderline personality disorder [letter]. June 998–999
Blow FC see Valenstein M
Bobes J see De la Fuente JM
Bockting CLH, Spinhoven P, Koeter MWJ, Wouters LF, Schene AH, for the Depression Evaluation Longitudinal Therapy Assessment (DELTA) Study Group. Prediction of recurrence in recurrent depression and the influence of consecutive episodes on vulnerability for depression: a 2-year prospective study. May 747–755
Boellner SW see Biederman J
Boerescu D see Zimmerman M
Boeve BF. Review of the non-Alzheimer dementias. Dec 1985–2001
Bogetto F see Bellino S
Bohn MJ, Swift RM. Prevalence and impact of alcohol dependence. Suppl 14, 6–13
BOLDER Study Group see Hirschfeld RMA
Borba CP see Henderson DC
Borek LL, Kohn R, Friedman JH. Mood and sleep in Parkinson's disease. June 958–963
Borrelli DJ see Nierenberg AA; Ostacher MJ
Bose A see Kornstein SG
Bossie CA see Gharabawi GM; Simpson GM
Bourgeois JA see Bacalman S
Bowden CL, Swann AC, Calabrese JR, Rubenfaer LM, Wozniak PJ, Collins MA, Abi-Saab W, Saltarelli M, for the Depakote ER Mania Study Group. Randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. Oct 1501–1510
Bowden CL see Frye MA
Bracha HS, Hayashi K. Resilience in the aftermath of terrorism and during warzone exposure: is it religiousness or is it number of blood relatives? [letter with reply]. July 1156
Brambilla P see Cipriani A
Brauer L see Biederman J
Brawman-Mintzer O, Knapp RG, Nietert PJ. Reply to Kopecek M, Mohr P, Novak T. Sedative effects of low-dose risperidone in GAD patients and risk of drug interactions [letter]. Aug 1307–1308
Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. June 874–881
Briggs SD see Cavazzoni PA
Brizee TJ see Gardner HH
Brook RA see Gardner HH
Brook S see Citrome L
Brown CH see Kelly DL

Brown EB, McElroy SL, Keck PE Jr, Deldar A, Adams DH, Tohen M, Williamson DJ. 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. July 1025–1033
Brown EB see Perlis RH
Brown ES. Introduction. The challenges of dual diagnosis: managing substance abuse in severe mental illness. Suppl 7, 3–4
Brown ES. Management of comorbid bipolar disorder and substance abuse. Aug e05
Brown ES see Buckley PF; Deas D; Green AI; Vornik LA
Brown RP see Sageman S
Bruijn JA see Birkenhäger TK ; van den Broek WW
Brunette MF, Mueser KT. Psychosocial interventions for the long-term management of patients with severe mental illness and co-occurring substance use disorder. Suppl 7, 10–17
Brunnauer A, Laux G, Geiger E, Soyka M, Möller H-J. Antidepressants and driving ability: results from a clinical study. Nov 1776–1781
Bryant RA. Recovery after the tsunami: timeline for rehabilitation. Suppl 2, 50–55
Bryant RA, Njenga FG. Cultural sensitivity: making trauma assessment and treatment plans culturally relevant. Suppl 2, 74–79
Buchanan RW see Nelson MW
Buckley PF. Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. Suppl 7, 5–9
Buckley PF, Brown ES. Prevalence and consequences of dual diagnosis. July e01
Buckley PF see Weiden PJ
Burke AK see Dervic K
Burke M see Dunner DL
Burke-Martindale CH see White MA
Cagliero E see Henderson DC
Cailhol L see Damsa C
Caine ED. Clinical perspectives on atypical antipsychotics for treatment of agitation. Suppl 10, 22–31
Cairney J see Schaffer A
Calabrese JR see Bowden CL; Frye MA; Gao K; Keck PE Jr
Calhoun PS see Clancy CP
Calkins AW see Nierenberg AA
Callan JA see Trivedi MH
Canino G see Alegria M
Canuso CM see Gharabawi GM
Carlson BX see Keck PE Jr
Carlson GA see Connor DF
Carlson JL see Kryzhanovskaya LA
Carlson MM see Pilowsky DJ
Carlsson R see Flyckt L
Carmody TJ see Toprac MG
Caroff K see Szanto K
Carpenter LL, Schecter JM, Tyrka AR, Mello AF, Mello MF, Haggarty R, Price LH. Open-label tiagabine monotherapy for major depressive disorder with anxiety. Jan 66–71
Carpenter LL see Wier LM
Carson WH see Keck PE Jr
Carter RE, Rickels K. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. June 874–881
Carter RE see Brawman-Mintzer O
Carter WG III, Shillcutt SD. Aripiprazole augmentation of venlafaxine in the treatment of psychogenic excoriation [letter]. Aug 1311
Case MG see Corya SA
Caselli RJ, Beach TG, Yaari R, Reiman EM. Alzheimer's disease a century later. Nov 1784–1800
Castberg I, Spigset O. Risperidone and lamotrigine: no evidence of a drug interaction [letter]. July 1159
Cather C see Henderson DC
Cavazzoni PA, Berg PH, Kryzhanovskaya LA, Briggs SD, Roddy TE, Tohen M, Kane JM. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. Jan 107–113
Cavazzoni PA see Kryzhanovskaya LA
Cerda G see Pilowsky DJ
Cerise FP see Ursano RJ
Chambers AS see Allen JJB
Chambers JE see Erickson CA
Chand PK, Murthy P, Anand S. Reply to Aukst-Margetic B: Monosymptomatic hypochondriacal psychosis or tardive dystonia? [letter] Feb 329
Chang JS, Ha K-S, Lee KY, Kim YS, Ahn YM. Effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. Mar 461–467
Chang KD see Connor DF
Charuvastra A, Yaeger D. Tactile hallucinations associated with therapeutic doses of bupropion in 2 patients [letter]. Nov 1820–1821
Chelminski I see Zimmerman M
Chen C-K see Lin S-K
Chen H, Reeves JH, Fincham JE, Kennedy WK, Dorfman JH, Martin BC. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001. June 972–982
Chengappa KNR, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR, for the Clinical Affairs Product Support Study–168 Investigators. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. Nov 1698–1706
Chessick CA see Bauer MS
Cheung AH see Schaffer A
Chiles C. Review of Wise MG, Rundell JR: *Clinical Manual of Psychosomatic Medicine: A Guide to Consultation-Liaison Psychiatry.* May 841
Chin B see Ha JH
Chiricolo G see Leo R
Cho IH see Ha JH
Choi J-S see Kwon JS
Christian KM see Simon NM
Cicotti A see Damsa C
Cipriani A, Barbui C, Brambilla P, Furukawa TA, Hotopf M, Geddes JR. Are all antidepressants really the same? the case of fluoxetine: a systematic review. June 850–858
Cipriani A see Barbui C
Citrome L, Volavka J, Czobor P, Brook S, Loebel A, Mandel FS. Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, open-label study data. April 638–642
Clancy CP, Graybeal A, Tompson WP, Badgett KS, Feldman ME, Calhoun PS, Erkanli A, Hertzberg MA, Beckham JC. Lifetime trauma exposure in veterans with military-related posttraumatic stress disorder: association with current symptomatology. Sept 1346–1353
Clarke LA, Lindenmayer J-P, Kaushik S. Clozapine augmentation with aripiprazole for negative symptoms [letter]. Apr 675–676
Clayton AH. Female sexual dysfunctions: what controversy? June 991–992
Clayton AH, Croft HA, Horrigan JP, Wightman DS, Krishen A, Richard NE, Modell JG. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. May 736–746
Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. Suppl 6, 33–37
Clayton AH see Nutt DJ
Clinical Affairs Product Support Study–168 Investigators see Chengappa KNR
Cluver JS, Hardesty SJ. Propofol for severe, refractory mania: a case report [letter]. Jan 165–166
Cogswell J see Bacalman S
Cohen H, Matar MA, Kaplan Z. Reply to Bracha HS, Hayashi K: Resilience in the aftermath of terrorism and during warzone exposure: is it religiousness or is it number of blood relatives? [letter]. July 1156–1157
Cohen H see Miodownik C
Cohen LS see Joffe H
Cola C see Leo R
Collins DM see Alessi-Severini S
Collins MA see Bowden CL
Colom F see Vieta E
Comes M see Vieta E
Compton W see Conway KP
Conley RR see Jung D-U; Kelly DL
Connor DF, Carlson GA, Chang KD, Daniolos PT, Ferziger R, Findling RL, Hutchinson JG, Malone RP, Halperin JM, Plattner B, Post RM, Reynolds DL, Rogers KM, Saxena K, Steiner H, for the Stanford/Howard/AACAP Workgroup on Juvenile Impulsivity and Aggression. Juvenile maladaptive aggression: a review of prevention, treatment, and service configuration and a proposed research agenda. May 808–820
Connor KM. Assessment of resilience in the aftermath of trauma. Suppl 2, 46–49

Connor KM, Cook JL, Davidson JRT. Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial. Jan 30–36
Connor KM, Foa EB, Davidson JRT. Practical assessment and evaluation of mental health problems following a mass disaster. Suppl 2, 26–33
Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Feb 247–257
Cook JL see Connor KM
Cooper J see Kapur N
Copeland PM see Henderson DC
Cordioli AV see Sousa MB
Corey-Lisle PK see Guo JJ
Correll CU. Real-life switching strategies with second-generation antipsychotics [ASCP Corner]. Jan 160–161
Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. Apr 575–583
Corry JC see Ball JR
Corya SA, Perlis RH, Keck PE Jr, Lin DY, Case MG, Williamson DJ, Tohen MF. 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. May 798–806
Coryell W see Solomon DA
Coughlin JF see Fried R
Crespo JM see Labad J
Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla ML, Martínez-García O, LLorca J, Vázquez-Barquero JL. Practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. Oct 1511–1521
Crespo-Facorro B see Álvarez-Jiménez M
Crismon ML see Toprac MG
Crits-Christoph P see Ninan PT
Croft HA see Clayton AH
Crossman AM, Lindenmayer JP. Tolerability of high-dose aripiprazole in treatment-refractory schizophrenic patients. July 1158–1159
Cullberg J see Flyckt L
Culpepper L. Primary care treatment of attention-deficit/hyperactivity disorder. Suppl 8, 51–58
Culpepper L. Social anxiety disorder in the primary care setting. Suppl 12, 31–37
Currier D see Dervic K
Czekalla J see Lambert M
Czobor P see Citrome L
D'Alessio DA see McElroy SL
Daley TB see Henderson DC
Damsa C, Warczyk S, Cailhol L, Kelley-Puskas AM, Cicotti A, Lazignac C, Andreoli A. Panic attacks associated with topiramate [letter]. Feb 326–327
Daniolos PT see Connor DF
Danker-Hopfe H see Bajbouj M
Davidson JRT. Foreword. After the tsunami: mental health challenges to the community for today and tomorrow. Suppl 2, 3–8
Davidson JRT. Pharmacologic treatment of acute and chronic stress following trauma: 2006. Suppl 2, 34–39
Davidson JRT. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? Suppl 12, 20–26
Davidson JRT, McFarlane AC. Extent and impact of mental health problems after disaster. Suppl 2, 9–14
Davidson JRT see Connor KM; Ninan PT
Davis CE see Depp CA
Davis JM see Freeman MP; Glick ID; Janowsky DS
Dawson DA see Grant BF; Huang B
Deas D. Adolescent substance abuse and psychiatric comorbidities. Suppl 7, 18–23
Deas D, Brown ES. Adolescent substance abuse and psychiatric comorbidities. July e02
De Castro P see Lopez-Garcia P
De Hert M, Kalnicka D, van Winkel R, Wampers M, Hanssens L, Van Eyck D, Scheen A, Peuskens J. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. Dec 1889–1896
De Hert M see van Winkel R
Deisenhammer EA see Laimer M
De la Fuente JM, Bobes J, Vizuete C, Bascaran M-T, Morlán I, Mendlewicz J. Neurologic soft signs in borderline personality disorder. Apr 541–546
DelBello MP. Focus on childhood and adolescent mental health [editorial]. Jan 5–6
DelBello MP. Improving the recognition and treatment of childhood and adolescent mental illness. May 807
DelBello MP. Past, future, and present of childhood and adolescent mental health. Jan 114
DelBello MP. Phenomenological considerations of childhood and adolescent psychopathology. Sept 1441
Deldar A see Brown EB
de Leon J see Baca-García E; Markham-Abedi C
Delgado PL. Monoamine depletion studies: implications for antidepressant discontinuation syndrome. Suppl 4, 22–26
Delgado PL see Moreno FA; Schatzberg AF
Dell'Osso B, Nestadt G, Allen A, Hollander E. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review. Apr 600–610
DeMartino R see Ursano RJ
Deneys ML, Ahearn EP. Exacerbation of PTSD symptoms with use of duloxetine [letter]. Mar 496–497
Dennehy EB see Bauer MS; Toprac MG
Depakote ER Mania Study Group see Bowden CL
Depp CA, Davis CE, Mittal D, Patterson TL, Jeste DV. Health-related quality of life and functioning of middle-aged and elderly adults with bipolar disorder. Feb 215–221
de Prado-Cumplido M see Baca-García E
Depression Evaluation Longitudinal Therapy Assessment (DELTA) Study Group see Bockting CLH
Dervic K, Oquendo MA, Currier D, Grunebaum MF, Burke AK, and Mann JJ. Moral objections to suicide: can they counteract suicidality in patients with cluster B psychopathology? Apr 620–625
De Santis M see Djulus J
Despiegel N see Stein DJ
Desrosiers A see Nierenberg AA
Deuschle M see Weber-Hamann B
Dew MA see Blank S
Diav-Citrin O see Djulus J
Di Lorenzo G see Leo R
Dixon LB see Kelly DL
Djulus J, Koren G, Einarson TR, Wilton L, Shakir S, Diav-Citrin O, Kennedy D, Lavigne SV, De Santis M, Einarson A. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. Aug 1280–1284
Doghramji PP. Trends in the pharmacologic management of insomnia. Suppl 13, 5–8
Dolberg OT see Bandelow B; Stein DJ
Dolder CR see Ascher-Svanum H
Dorfman JH see Chen H
Dougherty DD, Loh R, Jenike MA, Keuthen NJ. Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both? July 1086–1092
Downing M see Trivedi MH
Doyle AE. Executive functions in attention-deficit/hyperactivity disorder. Suppl 8, 21–26
Driessen M, Schroeder T, Widmann B, von Schönfeld C-E, Schneider F. Childhood trauma, psychiatric disorders, and criminal behavior in prisoners in Germany: a comparative study in incarcerated women and men. Oct 1486–1492
Duff D see Rickels K
Duggal HS, Mendhekar DN. High-dose aripiprazole in treatment-resistant schizophrenia [letter]. Apr 674–675
Dunckley T see Papassotiropoulos A
Dunner DL. Review of Callahan DM, Berrios GE: *Reinventing Depression: A History of the Treatment of Depression in Primary Care, 1940–2004*. Jan 168
Dunner DL, Rush AJ, Russell JM, Burke M, Woodard S, Wingard P, Allen J. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. May 688–695
Dunner DL see Shelton RC
Durkalski VL see Robert S
Dyck IR see Mancebo MC
Earl CQ see Biederman J; Swanson JM
Ebenbichler CF see Laimer M
Ebmeier KP see Herrmann LL
Edin HM see Williams VSL
Edman G see Flyckt L
Edwards NB. Review of Caroff SN, Mann SC, Francis A, Fricchione GL: *Catatonia: From Psychopathology to Neurobiology*. Apr 678–679

Egberts ACG see Hugenholtz GWK
Egberts TCG see Goedhard LE
Eichhammer P see Langguth B
Eidelman P see Ostacher MJ
Einarson A see Djulus J
Einarson TR see Djulus J
Einav S see Weiniger CF
Eisen JL see Mancebo MC; Pinto A
Ejnell H see Merrill CA
Eleff MK see Alessi-Severini S
Elgie R. Patient and primary care perspective: a patient's perspective on the treatment of depression. Suppl 6, 38–40
Elgie R see Nutt DJ
Elhai JD see Richardson JD
Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus DJH, Turner HJ. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. Nov 1707–1712
Emslie GJ see Wagner KD
Endicott J see Solomon DA
Engel RR see Pitschel-Walz G
Engh JA see Birkenaes AB
Engl J see Laimer M
Epstein LC. Review of Hales RE, Yudofsky SC, Chew RH (eds): *What Your Patients Need to Know About Psychiatric Medications*. Oct 1655
Erickson CA, Chambers JE. Memantine for disruptive behavior in autistic disorder [letter]. June 1000
Ericson GM see Ostacher MJ
Erkanli A see Clancy CP
Erman MK. Influence of pharmacokinetic profiles on safety and efficacy of hypnotic medications. Suppl 13, 9–12
Ernst CL, Bird SA, Goldberg JF, Ghaemi SN. Prescription of psychotropic medications for patients discharged from a psychiatric emergency service. May 720–726
Ernst FR see Ascher-Svanum H
Ertem-Vehid H see Sar V
Essock SM see Weissman EM
Etemad B see Stunkard AJ
Evans DL see Musselman DL
Evins AE see Henderson DC
Eyre J see Heru AM
Fagiolini A see Pollack MH; Thompson WK; Wildes JE
Fahim C see Mancini-Marie A
Farabaugh A see Trivedi MH
Faraone SV, Khan SA. Candidate gene studies of attention-deficit/hyperactivity disorder. Suppl 8, 13–20
Faraone SV see Biederman J; Spencer TJ
Farfel GM see Kornstein SG
Faries DE see Ascher-Svanum H
Farzin F see Bacalman S
Fava M. Prospective studies of adverse events related to antidepressant discontinuation. Suppl 4, 14–21
Fava M, Graves LM, Benazzi F, Scalia MJ, Iosifescu DV, Alpert JE, Papakostas GI. Cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. Nov 1754–1759
Fava M, Nurnberg HG, Seidman SN, Holloway W, Nicholas S, Tseng L-J, Stecher VJ. Efficacy and safety of sildenafil in men with serotonergic antidepressant–associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial. Feb 240–246
Fava M see Papakostas GI; Pilowsky DJ; Schatzberg AF; Trivedi MH
Fayyad R see Kornstein SG
Fehnel SE see Williams VSL
Feifel D see Ballon JS
Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. Sept 1354–1361
Feinberg SS, Moldawsky RJ. Psychiatric genetics [letter with reply]. Feb 324
Feldman ME see Clancy CP
Ferziger R see Connor DF
Fiedler U see Wolf J
Fincham JE see Chen H
Finder SG. Review of Ottosson J-O, Fink M: *Ethics in Electroconvulsive Therapy*. Dec 2036
Findling RL. Reply to Slaff I: Response to the management of autism and its related disorders [letter]. Dec 2031
Findling RL see Connor DF; Wagner KD
Finn CT, Blacker D, Sklar P, Smoller JW. Reply to Feinberg SS: Psychiatric genetics [letter]. Feb 324–325
Fiorillo A see Maj M
Fischer P see Grünblatt E
Fischmann D see Simon NM
Fitzgerald RG. Review of Wedding D, Boyd MA, Niemiec RM: *Movies & Mental Illness: Using Films to Understand Psychopathology, 2nd ed*. June 1002–1003
Flessner CA see Woods DW
Flyckt L, Mattsson M, Edman G, Carlsson R, Cullberg J. Predicting 5-year outcome in first-episode psychosis: construction of a prognostic rating scale. June 916–924
Foa EB. Psychosocial therapy for posttraumatic stress disorder. Suppl 2, 40–45
Foa EB. Social anxiety disorder treatments: psychosocial therapies. Suppl 12, 27–30
Foa EB, Stein DJ, McFarlane AC. Symptomatology and psychopathology of mental health problems after disaster. Suppl 2, 15–25
Foa EB see Connor KM; Simpson HB
Fogel SP, Sneed JR, Roose SP. Survey of psychiatric treatment among psychiatric residents in Manhattan: evidence of stigma. Oct 1591–1598
Fombonne E . Reply to Slaff I: Response to the management of autism and its related disorders [letter]. Dec 2030–2031
Fonseca M, Soares JC, Hatch JP, Santin AP, Kapczinski F. An open trial of adjunctive escitalopram in bipolar depression. Jan 81–86
Foris JM see Joffe H
Forleo GB see Leo R
Fostick L see Karamustafalioglu OK
Fountoulakis M see Papassotiropoulos A
Frank E see Szanto K; Thompson WK
Franklin ME see Woods DW
Frederickson AM see Correll CU
Freedman S see Weiniger CF
Freeman AM III. Review of Spiegel H, Spiegel D: *Trance and Treatment: Clinical Uses of Hypnosis, 2nd ed*. Feb 331
Freeman MP. Depression: what's sex got to do with it? Oct 1610–1611
Freeman MP. Evidence-based psychiatry and pregnancy. Aug 1278–1279
Freeman MP. Moving the field forward: new data regarding women's mental health. Feb 287
Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, Keck PE Jr, Marangell LB, Richardson AJ, Lake J, Stoll AL. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. Dec 1954–1967
Freeman MP see Gelenberg AJ; Moreno FA
Freudenreich O see Henderson DC
Fried R, Petty CR, Surman CB, Reimer B, Aleardi M, Martin JM, Coughlin JF, Biederman J. Characterizing impaired driving in adults with attention-deficit/hyperactivity disorder: a controlled study. Apr 567–574
Friedman JH see Borek LL
Friedman M see Zimmerman M
Friis S see Birkenaes AB
Frueh BC see Grubaugh AL
Frye MA, Yatham LN, Calabrese JR, Bowden CL, Ketter TA, Suppes T, Adams BE, Thompson TR. Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. Nov 1721–1728
Frye MA see Altshuler LL
Fujita T see Kaneita Y
Furukawa TA see Cipriani A
Gadow K see Weiss MD
Gajwani P see Gao K
Gal M see Karamustafalioglu OK
Gameroff MJ, Olfson M. Major depressive disorder, somatic pain, and health care costs in an urban primary care practice. Aug 1232–1239
Gameroff MJ see Blanco C
Gandhi C see Kornstein SG
Gane LW see Bacalman S
Ganoczy D see Valenstein M
Gao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. Sept 1327–1340
Garber J see Pilowsky DJ
Garbutt JC. Emerging pharmacologic treatments for alcohol dependence. Suppl 14, 35–40
Garbutt JC. New therapeutic options for alcohol dependence: long-acting intramuscular formulations of naltrexone. Suppl 14, 30–34
Gardner HH, Kleinman NL, Brook RA, Rajagopalan K, Brizee TJ, Smeeding JE. Economic impact of bipolar disorder in an employed population from an employer perspective. Aug 1209–1218

Gasto C see Plana MT
Geddes JR see Cipriani A
Geiger E see Brunnauer A
Gelenberg AJ. Tooting our horn [editorial]. Feb 178
Gelenberg AJ, Freeman MP. Circle of honor [editorial]. Mar 341
Gelenberg AJ, Kocsis JH, McCullough JP Jr, Ninan PT, Thase ME. State of knowledge of chronic depression [commentary]. Feb 179–184
Gentzler AL see Liu X
Gerevich J, Bácskai E. Intimate partner violence, suicidal intent, and alcoholism [letter]. Dec 2033–2034
Gerst M see Langguth B
Ghaemi SN see Ernst CL; Manwani SG; Pollack MH
Gharabawi GM, Bossie CA, Mahmoud R, Canuso CM, Lasser RA, Turkoz I, Greenspan A. Methodological issues in a comparative study of ziprasidone and risperidone [letter with reply]. Jan 162–164
Gharabawi GM see Simpson GM
Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang R-h. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. Feb 222–232
Gignac M see Wilens TE
Gilles M see Weber-Hamann B
Gillespie JA see Kornstein SG
Glatt SJ see Spencer TJ
Glazer WM. Overview: importance of recognizing and treating insomnia. Suppl 13, 3–4
Glick ID. Combining pharmacotherapy with psychotherapeutic management: guidelines for integration [ASCP Corner]. Oct 1645–1646
Glick ID, Marder SR. Reply to Adetunji B: Methodological issues in a study of long-term maintenance therapy with quetiapine versus haloperidol decanoate [letter]. Mar 497–498
Glick ID, Pham D, Davis JM. Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. Aug 1261–1265
Goedhard LE, Stolker JL, Heerdink ER, Nijman HLI, Olivier B, Egberts TCG. Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: a systematic review. July 1013–1024
Goetz RR see Weissman EM
Goff DC see Henderson DC
Göğüş A see Akdede BBK
Goikolea JM see Plana MT; Vieta E
Goldberg JF see Ernst CL
Goldstein BI, Levitt AJ. Factors associated with temporal priority in comorbid bipolar I disorder and alcohol use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Apr 643–649
Goldstein BI, Levitt AJ. Gender-focused perspective on health service utilization in comorbid bipolar I disorder and alcohol use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. June 925–932
Goldstein BI, Velyvis VP, Parikh SV. The association between moderate alcohol use and illness severity in bipolar disorder: a preliminary report. Jan 102–106
Goldstein MZ. Review of Ketter TA (ed): *Advances in Treatment of Bipolar Disorder*. Oct 1654–1655
Goldstein RB see Grant BF; Huang B
González-Blanch C see Álvarez-Jiménez M
Goodkin R see Musselman DL
Goodlin-Jones BL see Bacalman S
Goodwin FK see Manwani SG
Goodwin RD see Woods DW
Gorji A see Vakili N
Gracious BL see Wagner KD
Graepel J see Kroenke K
Graham JA see Ketter TA
Grant BF, Hasin DS, Stinson FS, Dawson DA, Goldstein RB, Smith S, Huang B, Saha TD. Epidemiology of DSM-iV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Mar 363–374
Grant BF see Alegria M; Conway KP; Huang B
Grant JE. SPECT imaging and treatment of pyromania [letter]. June 998
Graves LM see Fava M
Graybeal A see Clancy CP
Green AI. Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches. Suppl 7, 31–35
Green AI, Brown ES. Comorbid schizophrenia and substance abuse. Sept e08
Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. Oct e12
Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. Suppl 9, 3–8
Greenberg BD see Mancebo MC
Greenhill LL see Swanson JM
Greenspan A see Gharabawi GM
Greeven A, van Balkom AJLM, van Rood YR, van Oppen P, Spinhoven P. Boundary between hypochondriasis and obsessive-compulsive disorder: a cross-sectional study from the Netherlands. Nov 1682–1689
Greist JH see Ketter TA
Grigsby J see Bacalman S
Grilo CM see Rosenberger PH; White MA
Grubaugh AL, Frueh BC. Intimate partner violence victimization among adults with severe mental illness: results of a cross-sectional study [letter]. Sept 1472–1473
Grünblatt E, Löffler C, Zehetmayer S, Jungwirth S, Tragl K-H, Riederer P, Fischer P. Association study of the 5-HTTLPR polymorphism and depression in 75-year-old nondemented subjects from the Vienna Transdanube Aging (VITA) study. Sept 1373–1378
Grunebaum MF see Dervic K
Grunze H see Altshuler LL
Guerdjikova AI see McElroy SL
Guo JJ, Keck PE Jr, Corey-Lisle PK, Li H, Jiang D, Jang R, L'Italien GJ. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. July 1055–1061
Guo Y see Musselman DL
Güveli M see Karamustafalioglu OK
Gyulai L see Joffe H
Ha JH, Yoo HJ, Cho IH, Chin B, Shin D, Kim JH. Psychiatric comorbidity assessed in Korean children and adolescents who screen positive for Internet addiction. May 821–826
Ha K-S see Chang JS
Haatainen KM see Heiskanen TH
Haddad PM see Schatzberg AF
Hagen M see Berner MM
Hagerman RJ see Bacalman S
Haggarty R see Carpenter LL
Hajak M see Langguth B
Halperin JM see Connor DF
Haman KL. Review of Taylor S, Asmundson GJG: *Treating Health Anxiety: A Cognitive-Behavioral Approach*. Feb 330
Haman KL see Shelton RC
Hamann J see Heres S
Hamer RM see Zhong KX
Hammerness PG see Wilens TE
Hamner MB see Robert S
Hampton KD see Jefferson JW
Hankey GJ see Almeida OP
Hanssens L see De Hert M; van Winkel R
Harano S see Kaneita Y
Hardesty SJ see Cluver JS
Harlow BL see Joffe H
Harvey PD. Cognitive and functional effects of atypical antipsychotic medications. Oct e13
Harvey PD. Defining and achieving recovery from bipolar disorder. Suppl 9, 14–18
Harvey PD. Outcomes to monitor when treating bipolar disorder or schizophrenia. Aug e06
Hasan AM, Rifkin A, Mendelowitz AJ, Marchesi G, Lesser E, Russ M, Bernstein MB. Methadone hydrochloride to prevent impulsive behavior in mental retardation: a case report [letter]. Dec 2032–2033
Hasin D see Nunes EV
Hasin DS see Grant BF; Huang B
Hatch JP see Fonseca M
Hayashi K see Bracha HS
Hayden DL see Henderson DC
Hechtman L see Weiss M
Heerdink ER see Goedhard LE; Hugenholtz GWK
Hegerl U see Sterr A
Heiskanen TH, Niskanen LK, Hintikka JJ, Koivumaa-Honkanen HT, Honkalampi KM, Haatainen KM, Viinamäki HT. Metabolic syndrome and depression: a cross-sectional analysis. Sept 1422–1427

Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, Evins AE, Zhang H, Hayden DL, Freudenreich O, Cather C, Schoenfeld DA, Goff DC. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. May 789–797
Henderson KE see Rosenberger PH
Henin A see Biederman J
Heo M see Stunkard AJ
Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. Dec 1948–1953
Heres S see Leucht S
Herrmann LL, Ebmeier KP. Factors modifying the efficacy of transcranial magnetic stimulation in the treatment of depression: a review. Dec 1870–1876
Hertzberg MA see Clancy CP
Heru AM, Stuart GL, Rainey S, Eyre J, Recupero PR. Prevalence and severity of intimate partner violence and associations with family functioning and alcohol abuse in psychiatric inpatients with suicidal intent. Jan 23–29
Hess EV see Arnold LM
Heuser I see Bajbouj M; Weber-Hamann B
Hibbeln JR see Freeman MP
Higuchi H see Takahashi H
Hillemacher T, Bleich S, Nowak M, Meyrer R. Psychotic episode possibly induced by light therapy in a nondemented patient [letter]. June 997–998
Hilliker SE see Papakostas GI
Hinterhuber H see Laimer M
Hintikka JJ see Heiskanen TH
Hirschfeld RMA. Introduction: an overview of the issues surrounding the recognition and management of bipolar disorder and comorbid anxiety. Suppl 1, 3–4
Hirschfeld RMA, Weisler RH, Raines SR, MacFadden W, Bolder Study Group. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: secondary analysis from a randomized, double-blind, placebo-controlled study. Mar 355–362
Hirschfeld RMA see Perlis RH; Shelton RC; Wagner KD
Hirshfeld-Becker DR see Biederman J
Hitt SK see Allen JJB
Ho S see Mathew SJ
Hoehn-Saric R. Facial hyperhidrosis–induced social fear alleviated with topiramate. July 1157
Hoek HW see van Harten PN
Hoge EA see Simon NM
Hogue SL see Williams VSL
Hollander E see Dell'Osso B; Kolevzon A; Wainberg ML
Hollis KA see Williams VSL
Holloway W see Fava M
Honcharik PL see Alessi-Severini S
Honkalampi KM see Heiskanen TH
Horrigan JP see Clayton AH
Hotopf M see Cipriani A
Houck PR see Blank S; Szanto K
Houston JP, Ahl J, Meyers AL, Kaiser CJ, Tohen M, Baldessarini RJ. Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. Aug 1246–1252
Houston JP see Ketter TA
Høyer EH see Qin P
Huang B, Dawson DA, Stinson FS, Hasin DS, Ruan WJ, Saha TD, Smith SM, Goldstein RB, Grant BF. Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: results of the National Epidemiologic Survey on Alcohol and Related Conditions. July 1062–1073
Huang B see Grant BF
Hudson JI see Arnold LM; McElroy SL
Hugenholtz GWK, Heerdink ER, Stolker JJ, Meijer WEE, Egberts ACG, Nolen WA. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses June 897–903
Hughes CW see Pilowsky DJ
Hulihan JF see Chengappa ..NR
Huppert JD see Simpson HB
Hutchinson JG see Connor DF
Huyser J see Ruhé HG
Hwang CH see Joffe H
Ichikawa L see Simon GE
Iosifescu DV see Fava M; Nierenberg AA
Irwin TW see Wainberg ML
Ishigooka J see Takahashi H
Isolan LR see Sousa MB
Isometsä ET see Mantere O
Iyengar M see Rickels K
Jain UR see Rybak YE
Jamal HH see Perlis RH
Jang J-H see Jung D-U
Jang R see Guo JJ
Janowsky DS, Barnhill LJ, Khalid AS, Davis JM. Relapse of aggressive and disruptive behavior in mentally retarded adults following antipsychotic drug withdrawal predicts psychotropic drug use a decade later. Aug 1272–1277
Jansen JF see Kryzhanovskaya LA
Jarskog LF, Lieberman JA. Neuroprotection in schizophrenia. Sept e09
Javaras KN see Arnold LM
Jayathilake K see Akdede BBK
Jefferson JW. Complex chemical concoctions [ASCP Corner]. Feb 322–323
Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD, Wightman DS, Modell JG. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. June 865–873
Jenike MA see Dougherty DD
Jeste DV see Depp CA; Kryzhanovskaya LA
Jiang D see Guo JJ
Jiang JG see Swanson JM
Jimenez-Genchi A. Immediate switching from moclobemide to duloxetine may induce serotonin syndrome [letter]. Nov 1821–1822
Joffe H, Kim DR, Foris JM, Baldassano CF, Gyulai L, Hwang CH, McLaughlin WL, Sachs GS, Thase ME, Harlow BL, Cohen LS. Menstrual dysfunction prior to onset of psychiatric illness is reported more commonly by women with bipolar disorder than by women with unipolar depression and healthy controls. Feb 297–304
Johnson RA see Mago R
Jonsdottir H see Birkenaes AB
Jonsson MAG see Merrill CA
Juckel G see Sterr A
Jung D-U, Conley RR, Kelly DL, Kim D-W, Yoon S-H, Jang J-H, Shin J-G, Shim J-C. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. Sept 1391–1396
Jungwirth S see Grünblatt E
Kahn JP. Agitated depression, panic anxiety, and clonazepam [letter]. Dec 2034
Kaiser CJ see Houston JP
Kales HC see Sajatovic M
Kalnicka D see De Hert M
Kamata M see Takahashi H
Kanaan RA, Kerwin RW. Lithium and clozapine rechallenge: a retrospective case analysis. May 756–760
Kane JM. Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) [ASCP Corner]. May 831–832
Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. Suppl 5, 9–14
Kane JM see Cavazzoni PA; Correll CU; Leucht S
Kaneita Y, Ohida T, Uchiyama M, Takemura S, Kawahara K, Yokoyama E, Miyake T, Harano S, Suzuki K, Fujita T. Relationship between depression and sleep disturbances: a Japanese nationwide general population survey. Feb 196–203
Kapczinski F see Fonseca M
Kaplan Z see Cohen H
Kapur N, Cooper J, King-Hele S, Webb R, Lawlor M, Rodway C, Appleby L. Repetition of suicidal behavior: a multicenter cohort study. Oct 1599–1609
Karamustafalioglu N see Karamustafalioglu OK
Karamustafalioglu OK, Zohar J, Güveli M, Gal M, Bakim B, Fostick L, Karamustafalioglu N, Sasson Y. Natural course of posttraumatic stress disorder: a 20-month prospective study of Turkish earthquake survivors. June 882–889
Karlsson M see Merrill CA
Karow A see Lambert M
Karp JF see Blank S
Kasper S see Montgomery SA
Kaufman B see Biederman J
Kaushik S see Clarke LA

Kawahara K see Kaneita Y
Keck PE Jr. Long-term management strategies to achieve optimal function in patients with bipolar disorder. Dec e17
Keck PE Jr. Long-term management strategies to achieve optimal function in patients with bipolar disorder. Suppl 9, 19–24
Keck PE Jr, Strawn JR, McElroy SL. Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. Suppl 1, 8–15
Keck PE Jr, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, Marcus RN, Sanchez R, for the Aripiprazole Study Group. Randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. Apr 626–637
Keck PE Jr see Altshuler LL; Arnold LM; Brown EB; Corya SA; Freeman MP; Guo JJ; McElroy SL; Perlis RH; Strawn JR
Keith J see Neugebauer R
Keitner GI, Ryan CE, Solomon DA. Realistic expectations and a disease management model for depressed patients with persistent symptoms. Sept 1412–1421
Keller MB. Prevalence and impact of comorbid anxiety and bipolar disorder. Suppl 1, 5–7
Keller MB. Social anxiety disorder clinical course and outcome: review of Harvard/Brown Anxiety Research Project (HARP) findings. Suppl 12, 14–19
Keller MB see Solomon DA
Kelley-Puskas AM see Damsa C
Kelly DL, Dixon LB, Kreyenbuhl JA, Medoff D, Lehman AF, Love RC, Brown CH, Conley RR. Clozapine utilization and outcomes by race in a public mental health system: 1994–2000. Sept 1404–1411
Kelly DL see Jung D-U
Kennedy A see Tapp AM
Kennedy D see Djulus J
Kennedy WK see Chen H
Kerwin RW see Kanaan RA
Ketter TA, Greist JH, Graham JA, Roberts JN, Thompson TR, Nanry KP. Effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial. Mar 400–406
Ketter TA, Houston JP, Adams DH, Risser RC, Meyers AL, Williamson DJ, Tohen M. Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. Jan 95–101
Ketter TA see Frye MA
Keuthen NJ see Dougherty DD; Woods DW
Khalid AS see Janowsky DS
Khan SA see Faraone SV
Khandker RK see McLaughlin TP; Simon GE
Kibari A see Miodownik C
Kidd M see Emsley R
Kiev A see Ninan PT; Shelton RC
Kim CH see Kwon JS
Kim CY see Kwon JS
Kim DR see Joffe H
Kim D-W see Jung D-U
Kim HM see Valenstein M
Kim JH see Ha JH
Kim YS see Chang JS
King CA see Pilowsky DJ
King-Hele S see Kapur N
Kinrys G, Wygant LE, Pardo TB, Melo M. Levetiracetam for treatment-refractory posttraumatic stress disorder. Feb 211–214
Kinrys G see Simon NM
Kiss E see Liu X
Kissling W see Heres S; Pitschel-Walz G
Klein DF. FDA post-marketing safety decisions. Aug 1305–1306
Kleinman NL see Gardner HH
Klibanski A see Papakostas GI
Klier CM, Schmid-Siegel B, Schäfer MR, Lenz G, Saria A, Lee A, Zernig G. St. John's Wort (*Hypericum perforatum*) and breastfeeding: plasma and breast milk concentrations of hyperforin for 5 mothers and 2 infants. Feb 305–309
Kline J see Neugebauer R
Knapp RG see Brawman-Mintzer O
Knight LJ see Viner MW
Knopf U see Zink M
Kocsis JH see Gelenberg AJ
Koen L see Emsley R
Koeter MWJ see Bockting CLH
Kohn R see Borek LL
Koivumaa-Honkanen HT see Heiskanen TH
Kolevzon A, Mathewson KA, Hollander E. Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability. Mar 407–414
Kondziella D, Arlien-Soborg P. Diagnostic and therapeutic challenges in narcolepsy-related psychosis [letter]. Nov 1817–1819
Kopecek M, Mohr P, Novak T. Sedative effects of low-dose risperidone in GAD patients and risk of drug interactions [letter with reply]. Aug 1307–1308
Koran LM see Ninan PT
Koren G see Djulus J
Kornstein SG, Bose A, Li D, Saikali KG, Gandhi C. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. Nov 1767–1775
Kornstein SG, Pearlstein TB, Fayyad R, Farfel GM, Gillespie JA. Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. Oct 1624–1632
Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE. Duloxetine efficacy for major depressive disorder in male vs female patients: data from 7 randomized, double-blind, placebo-controlled trials. May 761–770
Kothencné VO see Liu X
Kotler M see Amital D
Kotwal R see McElroy SL
Kovacs M see Liu X
Kowatch RA see Post RM
Kramer TAM. Review of Hollander E, Stein DJ: *Clinical Manual of Impulse-Control Disorders.* May 840–841
Kramer-Reinstadler K see Laimer M
Kreyenbuhl JA see Kelly DL
Krishen A see Clayton AH; Jefferson JW
Kriston L see Berner MM
Kroenke K, Messina N III, Benattia I, Graepel J, Musgnung J. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. Jan 72–80
Kruzikas DT see McLaughlin TP
Kryzhanovskaya LA, Jeste DV, Young CA, Polzer JP, Roddy TE, Jansen JF, Carlson JL, Cavazzoni PA. A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia. June 933–945
Kryzhanovskaya LA see Cavazzoni PA
Kugu N see Sar V
Kujawa M see Simpson GM
Kunkel EJS see Mago R
Kupfer DJ see Thompson WK
Kupka RW see Altshuler LL
Kuwilsky A see Zink M
Kwon JS, Choi J-S, Bahk W-M, Kim CY, Kim CH, Shin YC, Park B-J, Oh CG. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. Apr 547–553
Labad J, Urretavizcaya M, Crespo JM. Onset of unipolar depression or bipolar disorder prior or close to menarche [letter]. Dec 2032
Lacro JP see Ascher-Svanum H
Laimer M, Kramer-Reinstadler K, Rauchenzauner M, Lechner-Schoner T, Strauss R, Engl J, Deisenhammer EA, Hinterhuber H, Patsch JR, Ebenbichler CF. Effect of mirtazapine treatment on body composition and metabolism. Mar 421–424
Lake J see Freeman MP
Lake KA see McElroy SL
Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, Czekalla J. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. Nov 1690–1697
Landecho I see Lopez-Garcia P
Landgrebe M see Langguth B
Langguth B, Landgrebe M, Zowe M, Gerst M, Hajak M, Eichhammer P. Repetitive transcranial magnetic stimulation for maintenance treatment of depression: a case report [letter]. May 835–836
Lasser RA see Gharabawi GM; Simpson GM
Lauro R see Leo R
Laursen TM see Qin P
Laux G see Brunnauer A
Lavigne SV see Djulus J
Lawlor M see Kapur N
Lawson D see Musselman DL

Lawson K see Musselman DL
Lazignac C see Damsa C
Lechner-Schoner T see Laimer M
Leckman JF. Review of Gorman JM (ed.): *Fear and Anxiety: The Benefits of Translational Research.* Mar 499–500
Lecrubier Y. Physical components of depression and psychomotor retardation. Suppl 6, 23–26
Lecrubier Y see Nutt DJ
Lederbogen F see Weber-Hamann B
Lee A see Klier CM
Lee KY see Chang JS
Lee TA see Valenstein M
Leehey MA see Bacalman S
Lehman AF see Kelly DL
Leiva-Murillo JM see Baca-García E
Lenz G see Klier CM
Lenze EJ see Blank S
Leo R, Di Lorenzo G, Tesauro M, Razzini C, Forleo GB, Chiricolo G, Cola C, Zanasi M, Troisi A, Siracusano A, Lauro R, Romeo F. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. Nov 1760–1766
Leon AC see Solomon DA
Leppämäki S see Mantere O
Lerner V see Miodownik C
Lesser E see Hasan AM
Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. Suppl 5, 3–8
Leucht S, Kane JM. Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia [ASCP Corner]. Nov 1813–1814
Leucht S see Heres S
Leverich GS see Altshuler LL
Levin B see Neugebauer R
Levine J see Amital D
Levitan RD see Rybak YE
Levitt AJ see Goldstein BI; Schaffer A
Lewis-Fernández R, Blanco C, Mallinckrodt CH, Wohlreich MM, Watkin JG, Plewes JM. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in US Hispanic and majority caucasian patients. Sept 1379–1390
Lewison B see Musselman DL
Li D see Kornstein SG
Li H see Guo JJ
Lieberman JA. Neurobiology and the natural history of schizophrenia. Oct e14
Lieberman JA see Jarskog LF; Zhong KX
Liebowitz MR see Simpson HB
Lin C-Y, Wu P-L, Pariante CM, Su K-P. Crossover study of prolactin changes associated with risperidone and olanzapine [letter]. Sept 1470–1471
Lin DY see Corya SA
Lin J-J, Lu T-H. Association between the accessibility to lethal methods and method-specific suicide rates: an ecological study in Taiwan. July 1074–1079
Lin S-K, Chen C-K. Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: a case report [letter]. Aug 1307
Lindenmayer J-P see Clarke LA; Crossman AM
Liskow BI see Moeller KE
L'Italien GJ see Guo JJ
Liu HH see Pilowsky DJ
Liu X, Gentzler AL, Tepper P, Kiss E, Kothencné VO, Tamás Z, Vetró A, Kovacs M. Clinical features of depressed children and adolescents with various forms of suicidality. Sept 1442–1450
Liu X see Nunes EV
LLorca J see Crespo-Facorro B
Loebel A see Citrome L
Loebel AD see Addington DEN
Löffler C see Grünblatt E
Loh R see Dougherty DD
Lopez FA see Swanson JM; Biederman J
Lopez-Garcia P, Rodriguez JT, De Castro P, Landecho I, Zapata R. Association between clozapine-induced agranulocytosis and HLA subtyping [letter]. Oct 1652–1653
Lorberbaum JP see Robert S
Love RC see Kelly DL
Lu T-H see Lin J-J
Lundgren JD see Stunkard AJ
Luther JF see Trivedi MH
Lydiard RB see Shelton RC
Macfadden W see Hirschfeld RMA
Mackenzie BE see Rybak YE
Mackin P, Young AH. Reply to Vieweg WVR: QTc and metabolic parameters [letter]. May 839
MacQueen G see Taylor V
Madhusoodanan S, Moise D. Risperidone-induced hyperprolactinemia in adolescents: a case series. July 1110–1113
Magliano L see Maj M
Mago R, Anolik R, Johnson RA, Kunkel EJS. Recurrent priapism associated with use of aripiprazole [letter]. Sept 1471–1472
Mahmoud R see Gharabawi GM
Mahmoud RA see Simpson GM
Maj M, Pirozzi R, Magliano L, Fiorillo A, Bartoli L. Agitated "unipolar" major depression: prevalence, phenomenology, and outcome. May 712–719
Malaspina D. Schizophrenia: a neurodevelopmental or a neurodegenerative disorder. Aug e07
Malhi GS see Ball JR
Mallinckrodt CH see Kornstein SG; Lewis-Fernández R
Malloy E see Pilowsky DJ
Malone RP see Connor DF
Malvini L see Barbui C
Manatunga AK see Musselman DL
Manber R see Allen JJB
Mancebo MC, Eisen JL, Pinto A, Greenberg BD, Dyck IR, Rasmussen SA. Brown Longitudinal Obsessive Compulsive Study: treatments received and patient impressions of improvement. Nov 1713–1720
Mancebo MC see Pinto A
Mancini-Marïe A, Potvin S, Fahim C, Beauregard M, Mensour B, Stip E. Neural correlates of the affect regulation model in schizophrenia patients with substance use history: a functional magnetic resonance imaging study. Mar 342–350
Mandel FS see Citrome L; Ninan PT
Mane A see Plana MT
Manfro GG see Sousa MB
Mann JJ see Baca-García E; Dervic K
Mantere O, Melartin TK, Suominen K, Rytsälä HJ, Valtonen HM, Arvilommi P, Leppämäki S, Isometsä ET. Differences in Axis I and II comorbidity between bipolar I and II disorders and major depressive disorder. Apr 584–593
Manu P see Correll CU
Manwani SG, Pardo TB, Albanese MJ, Zablotsky B, Goodwin FK, Ghaemi SN. Substance use disorder and other predictors of antidepressant-induced mania: a retrospective chart review. Sept 1341–1345
Marangell LB see Bauer MS; Freeman MP; Trivedi MH
Marchesi G see Hasan AM
Marcus MD see Wildes JE
Marcus RN see Keck PE Jr
Marder SR. Drug initiatives to improve cognitive function. Suppl 9, 31–35
Marder SR. Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness. July e03
Marder SR. Review of agitation in mental illness: treatment guidelines and current therapies. Suppl 10, 13–21
Marder SR. Review of Lawrie SM, Johnstone EC, Weinberger DR (eds): *Schizophrenia: From Neuroimaging to Neuroscience.* Dec 2035
Marder SR see Glick ID
Margetic B see Aukst-Margetic B
Markham-Abedi C, de Leon J. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report [letter]. Sept 1473–1474
Markowitz JC see Neugebauer R
Martin BC see Chen H
Martin JM see Fried R
Martin PR. Review of Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds): *Substance Abuse: A Comprehensive Textbook, 4th ed.* Sept 1475
Martínez-Arán A see Vieta E
Martínez-García O see Álvarez-Jiménez M; Crespo-Facorro B
Martino NS see Stunkard AJ
Maser JD see Solomon DA
Masheb RM see White MA
Masramon X see Vieta E
Matar MA see Cohen H
Mathew SJ, Ho S. Etiology and neurobiology of social anxiety disorder. Suppl 12, 9–13
Mathews M see Adetunji B
Mathewson KA see Kolevzon A
Matroos GE see van Harten PN
Matseoane K see Nunes EV
Mattsson M see Flyckt L

Matuszak JM see Viner MW
McCarthy JF see Valenstein M
McCullough JP Jr see Gelenberg AJ
McElroy SL, Kotwal R, Guerdjikova AI, Welge JA, Nelson EB, Lake KA, D'Alessio DA, Keck PE Jr, Hudson JI. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. Dec 1897–1906
McElroy SL see Altshuler LL; Brown EB; Keck PE Jr
McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. Suppl 5, 15–18
McFarlane AC see Davidson JRT, Foa EB
McGahuey CA see Moreno FA
McGirr A, Séguin M, Renaud J, Benkelfat C, Alda M, Turecki G. Gender and risk factors for suicide: evidence for heterogeneity in predisposing mechanisms in a psychological autopsy study. Oct 1612–1617
McKinney W see Trivedi MH
McLaughlin TP, Khandker RK, Kruzikas DT, Tummala R. Overlap of anxiety and depression in a managed care population: prevalence and association with resource utilization. Aug 1187–1193
McLaughlin WL see Joffe H
McLean LM see Ross LE
McNally RJ see Pollack MH
McNeely HE see Rybak YE
McQuade RD see Keck PE Jr
Medoff D see Kelly DL
Meijer WEE see Hugenholtz GWK
Melartin TK see Mantere O
Mello AF see Carpenter LL
Mello MF see Carpenter LL
Melo M see Kinrys G
Meltzer HY see Akdede BBK
Mendelowitz AJ see Hasan AM
Mendhekar DN see Duggal HS
Mendlewicz J see de la Fuente JM
Mensour B see Mancini-Marie A
Mergl R see Sterr A
Merideth CH. Single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults. Feb 258–262
Merrill CA, Jonsson MAG, Minthon L, Ejnell H, Silander HC, Blennow K, Karlsson M, Nordlund A, Rolstad S, Warkentin S, Ben-Menachem E, Sjögren MJC. Vagus nerve stimulation in patients with Alzheimer's disease: additional follow-up results of a pilot study through 1 year. Aug 1171–1178
Messina N III see Kroenke K
Meyers AL see Houston JP; Ketter TA
Meyrer R see Hillemacher T
Michelson D see Spencer TJ
Mick E see Biederman J
Miklowitz DJ. Review of evidence-based psychosocial interventions for bipolar disorder. Suppl 11, 28–33
Miklowitz DJ see Bauer MS
Miller AL see Toprac MG
Miller KK see Papakostas GI
Miller MD see Blank S
Minichiello WE see Baer L
Minthon L see Merrill CA
Mintz J see Altshuler LL
Mintzer JE. Introduction: clinical impact of agitation in various psychiatric disorders: management consensus and controversies. Suppl 10, 3–4
Miodownik C, Lerner V, Kibari A, Toder D, Cohen H. Effect of sudden clozapine discontinuation on management of schizophrenic patients: a retrospective controlled study. Aug 1204–1208
Mischoulon D see Freeman MP
Mitchell JE. Review of Munsch S, Beglinger C: *Obesity and Binge Eating Disorder*. Apr 679
Mitchell PB see Ball JR
Mittal D see Depp CA
Miyahara S see Pollack MH
Miyake T see Kaneita Y
Modafinil ADHD Study Group see Biederman J
Modell JG see Clayton AH; Jefferson JW
Moeller KE, Shireman TI, Liskow BI. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. Dec 1942–1947
Mohr P see Kopecek M
Moise D see Madhusoodanan S
Moldawsky RJ see Feinberg SS
Moleman P see Birkenhäger TK; van den Broek WW
Möller H-J see Brunnauer A
Montejo AL see Clayton AH; Nutt DJ
Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. May 771–782
Monuteaux MC see Biederman J
Mooney LJ, Tsuang J. Review of Kindon DG, Turkington D: *Cognitive Therapy of Schizophrenia*. June 1001
Moreno FA, McGahuey CA, Freeman MP, Delgado PL. Sex differences in depressive response during monoamine depletions in remitted depressive subjects. Oct 1618–1623
Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Nov 1735–1740
Moreno FA see Allen JJB
Morgenstern J see Wainberg ML
Morlán I see De la Fuente JM
Mortensen PB see Qin P
Muench F see Wainberg ML
Mueser KT see Brunette MF
Mulder PGH see van den Broek WW
Mulert C see Sterr A
Mulsant BH see Blank S
Murthy P see Chand PK
Musgnung J see Kroenke K
Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB. Double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. Feb 288–296
Muzina D see Gao K
Naber D see Lambert M; Phillips GA
Nanry KP see Ketter TA
Narrow WH see Blanco C
Nash JL. Review of Thompson JM, Cotlove C: *The Therapeutic Process: A Clinical Introduction to Psychodynamic Psychotherapy*. June 1002
Nelson EB see McElroy SL
Nelson JC see Jefferson JW
Nelson MW, Buchanan RW. Galantamine-induced QTc prolongation [letter]. Jan 166–167
Nemeroff CB see Musselman DL
Nestadt G see Dell'Osso B
Neugebauer R, Kline J, Markowitz JC, Bleiberg KL, Baxi L, Rosing MA, Levin B, Keith J. Pilot randomized controlled trial of interpersonal counseling for subsyndromal depression following miscarriage. Aug 1299–1304
Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. Nov e16
Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. Suppl 9, 25–30
Nguyen DD see Henderson DC
Nicholas S see Fava M
Niehaus DJH see Emsley R
Nierenberg AA, Ostacher MJ, Borrelli DJ, Iosifescu DV, Perlis RH, Desrosiers A, Armistead MS, Calkins AW, Sachs GS. Integration of measurement and management for the treatment of bipolar disorder: a STEP-BD model of collaborative care in psychiatry. Suppl 11, 3–7
Nierenberg AA see Ostacher MJ; Pollack MH; Trivedi MH
Nietert PJ see Kopecek M
Nijman HLI see Goedhard LE
Ninan PT, Koran LM, Kiev A, Davidson JRT, Rasmussen SA, Zajecka JM, Robinson DG, Crits-Christoph P, Mandel FS, Austin C. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. Jan 15–22
Ninan PT see Gelenberg AJ
Niskanen LK see Heiskanen TH
Njenga FG see Bryant RA; Otero JC
Nolen WA see Altshuler LL; Hugenholtz GWK
Nordentoft M see Qin P
Nordlund A see Merrill CA
Novak T see Kopecek M
Novick JS. Reply to Benazzi F: Atypical depression: category or specifier? [letter] June 996–997
Nowak M see Hillemacher T
Nunes EV, Liu X, Samet S, Matseoane K, Hasin D. Independent versus substance-induced major depressive disorder in substance-dependent patients: observational study of course during follow-up. Oct 1561–1567

Nurnberg HG see Fava M
Nutt DJ. Role of dopamine and norepinephrine in depression and antidepressant treatment. Suppl 6, 3–8
Nutt DJ, Baldwin DS, Clayton AH, Elgie R, Lecrubier Y, Montejo AL, Papakostas GI, Souery D, Trivedi MH, Tylee A. Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. Suppl 6, 46–49
Ofek H see Weiniger CF
Oh CG see Kwon JS
Ohida T see Kaneita Y
O'Leary A see Wainberg ML
Olfson M see Blanco C; Gameroff MJ
Oliveira RR see Sousa MB
Olivier B see Goedhard LE
Oosthuizen PP see Emsley R
Operskalski BH see Simon GE
Opjordsmoen S see Birkenaes AB
Oquendo MA see Baca-García E; Dervic K
O'Reardon JP see Stunkard AJ
Osinowo T see Adetunji B
Osone A, Takahashi S. Possible link between childhood separation anxiety and adulthood personality disorder in patients with anxiety disorders in Japan. Sept 1451–1457
Osser DN see Trivedi MH
Ostacher MJ. Evidence for antidepressant use in bipolar depression. Suppl 11, 18–21
Ostacher MJ, Nierenberg AA, Perlis RH, Eidelman P, Borrelli DJ, Tran TB, Ericson GM, Weiss RD, Sachs GS. Relationship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar disorder. Dec 1907–1911
Ostacher MJ, Sachs GS. Update on bipolar disorder and substance abuse: recent findings and treatment strategies. Sept e10
Ostacher MJ see Nierenberg AA
Otero JC, Njenga FG. Lessons in posttraumatic stress disorder from the past: Venezuela floods and Nairobi bombing. Suppl 2, 56–63
Otto MW see Pollack MH
Özen ME see Yumru M
Ozturk E see Sar V
Padberg F see Sterr A
Pagano ME see Pinto A
Pande AC see Montgomery SA
Pantelis C see Addington DEN
Papakostas GI, Miller KK, Petersen T, Sklarsky KG, Hilliker SE, Klibanski A, Fava M. Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. June 952–959
Papakostas GI see Baldwin DS; Fava M; Nutt DJ; Souery D
Papassotiropoulos A, Fountoulakis M, Dunckley T, Stephan DA, Reiman EM. Genetics, transcriptomics, and proteomics of Alzheimer's disease. Apr 652–670
Papp LA. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. Oct 1573–1576
Paradiso E see Bellino S
Pardo TB see Kinrys G; Manwani SG
Pariante CM see Lin C-Y
Parikh SV see Goldstein BI
Park B-J see Kwon JS
Parsons JT see Wainberg ML
Patsch JR see Laimer M
Patterson TL see Depp CA
Pearlstein TB see Kornstein SG
Pedlar DJ see Richardson JD
Peet M see Freeman MP
Penna S see Musselman DL
Pérez-Iglesias R see Álvarez-Jiménez M; Crespo-Facorro B
Pérez-Pardal T see Álvarez-Jiménez M
Perez-Rodriguez MM see Baca-García E
Perlis RH, Baker RW, Zarate CA Jr, Brown EB, Schuh LM, Jamal HH, Tohen M. Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial. Nov 1747–1753
Perlis RH, Welge JA, Vornik LA, Hirschfeld RMA, Keck PE Jr. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. Apr 509–516
Perlis RH see Corya SA; Nierenberg AA; Ostacher MJ
Perlman C see Pollack MH
Peskind ER see Tapp AM
Petersen T see Papakostas GI
Petkova E see Simpson HB
Pettinati HM. Improving medication adherence in alcohol dependence. Suppl 14, 23–29
Petty CR see Biederman J; Fried R
Peuskens J see De Hert M; van Winkel R
Pham D see Glick ID
Phillips GA, Van Brunt DL, Roychowdhury SM, Xu W, Naber D. Relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. Sept 1397–1403
Pilowsky DJ, Wickramaratne PJ, Rush AJ, Hughes CW, Garber J, Malloy E, King CA, Cerda G, Sood AB, Alpert JE, Wisniewski SR, Trivedi MH, Talati A, Carlson MM, Liu HH, Fava M, Weissman MM. Children of currently depressed mothers: a STAR*D ancillary study. Jan 126–136
Pinto A, Mancebo MC, Eisen JL, Pagano ME, Rasmussen SA. Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake. May 703–711
Pinto A see Mancebo MC
Pirozzi R see Maj M
Pitman R see Pollack MH
Pitschel-Walz G, Bäuml J, Bender W, Engel RR, Wagner M, Kissling W. Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich Psychosis Information Project Study. Mar 443–452
Plana MT, Blanch J, Romero S, Serra M, Gasto C. Toxic catatonia secondary to azithromycin [letter]. Mar 492–493
Plana MT, Mane A, Benabarre A, Goikolea JM, Vieta E. Emergence of darkness phobia in a bipolar patient during quetiapine treatment [letter]. Apr 673–674
Plattner B see Connor DF
Plewes JM see Lewis-Fernández R
Podolski A see Wilens TE
Pogarell O see Sterr A
Pollack MH, Simon NM, Fagiolini A, Pitman R, McNally RJ, Nierenberg AA, Miyahara S, Sachs GS, Perlman C, Ghaemi SN, Thase ME, Otto MW. Persistent posttraumatic stress disorder following September 11 in patients with bipolar disorder. Mar 394–399
Pollack MH see Simon NM
Pollock BG see Blank S
Polzer JP see Kryzhanovskaya LA
Porter M see Musselman DL
Post RM, Kowatch RA. Health care crisis of childhood-onset bipolar illness: some recommendations for its amelioration. Jan 115–125
Post RM see Altshuler LL; Connor DF
Posternak MA see Zimmerman M
Potvin S see Mancini-Marie A
Prakash R. Review of Marneros A, Pillmann F: *Acute and Transient Psychoses.* Sept 1475–1476
Price LH see Carpenter LL; Wier LM
Priebe S see Bhui K
Prospero-Garcia KA, Torres-Ruiz A, Ramirez-Bermudez J, Velazquez-Moctezuma J, Arana-Lechuga Y, Teran-Perez G. Fluoxetine-mirtazapine interaction may induce restless legs syndrome: report of 3 cases from a clinical trial [letter]. Nov 1820
Qin P, Nordentoft M, Høyer EH, Agerbo E, Laursen TM, Mortensen PB. Trends in suicide risk associated with hospitalized psychiatric illness: a case-control study based on Danish longitudinal registers. Dec 1936–1941
Raeder MB, Bjelland I, Vollset SE, Steen VM. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. Dec 1974–1982
Raines SR see Hirschfeld RMA
Rainey S see Heru AM
Rainey SE see Recupero PR
Rajagopalan K see Gardner HH; Gianfrancesco FD
Ramirez-Bermudez J see Prospero-Garcia KA
Ramirez-Bonilla ML see Alvarez-Jimenez M; Crespo-Facorro B
Randall ET see Surman CBH
Rapaport MH see Shelton RC
Raskind MA see Tapp AM
Rasmussen SA see Mancebo MC; Ninan PT; Pinto A
Rauchenzauner M see Laimer M
Razzini C see Leo R
Recupero PR, Rainey SE. Characteristics of E-therapy Web sites. Sept 1435–1440
Recupero PR see Heru AM
Reed ML see Wagner KD

Reeves JH see Chen H
Regan WM. Review of Pies RW: *Handbook of Essential Psychopharmacology, 2nd ed.* Feb 330–331
Reifler BV. Review of Semple D, Smyth R, Burns J, Darjee R, McIntosh A: *Oxford Handbook of Psychiatry.* June 1001–1002
Reilly-Harrington N, Sachs GS. Psychosocial strategies to improve concordance and adherence in bipolar disorder. July e04
Reiman EM. Genetic, transcriptomic, and proteomic study of Alzheimer's disease. Apr 650–651
Reiman EM. In this issue: non-Alzheimer dementias. Dec 1983–1984
Reiman EM. 100-year update on Alzheimer's disease and related disorders. Nov 1782–1783
Reiman EM see Caselli RJ; Papassotiropoulos A
Reimer B see Fried R
Reimherr FW see Spencer TJ
Reissman DB see Ursano RJ
Renaud J see McGirr A
Reus VI. Review of Marneros A, Goodwin FK (eds): *Bipolar Disorders: Mixed States, Rapid Cycling, and Atypical Forms.* Nov 1823
Reynolds CF III see Blank S; Szanto K
Reynolds DL see Connor DF
Richard NE see Clayton AH
Richardson AJ see Freeman MP
Richardson JD, Elhai JD, Pedlar DJ. Association of PTSD and depression with medical and specialist care utilization in modern peacekeeping veterans in Canada with health-related disabilities. Aug 1240–1245
Rickels K, Rynn M, Iyengar M, Duff D. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. Jan 41–47
Rickels K see Brawman-Mintzer O; Feiger AD
Riederer P see Grünblatt E
Rifkin A see Hasan AM
Ringen PA see Birkenaes AB
Risser RC see Ketter TA
Robert S, Hamner MB, Ulmer HG, Lorberbaum JP, Durkalski VL. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. Oct 1522–1526
Roberts JN see Ketter TA
Robinson DG see Ninan PT
Robinson DS see Feiger AD
Roddy TE see Cavazzoni PA; Kryzhanovskaya LA
Rodriguez JT see Lopez-Garcia P
Rodriguez S see Simpson GM
Rodway C see Kapur N
Rogers KM see Connor DF
Roitman S see Amital D
Rollin LM see Keck PE Jr
Rolstad S see Merrill CA
Romano SJ see Addington DEN
Romeo F see Leo R
Romero S see Plana MT
Roose SP see Fogel SP
Rosenbaum JF see Biederman J
Rosenberger PH, Henderson KE, Grilo CM. Psychiatric disorder comorbidity and association with eating disorders in bariatric surgery patients: a cross-sectional study using structured interview–based diagnosis. July 1080–1085
Rosenthal NR see Chengappa KNR
Rosing MA see Neugebauer R
Ross LE, McLean LM. Anxiety disorders during pregnancy and the postpartum period: a systematic review. Aug 1285–1304
Rothschild BS see White MA
Roychowdhury SM see Phillips GA
Ruan WJ see Huang B
Rubenfaer LM see Bowden CL
Rüdell K see Bhui K
Ruggero CJ see Zimmerman M
Ruhé HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. Dec 1836–1855
Rush AJ see Dunner DL; Jefferson JW; Pilowsky DJ; Toprac MG; Trivedi MH
Russ M see Hasan AM
Russell JM see Dunner DL
Ryan CE see Keitner GI
Rybak YE, McNeely HE, Mackenzie BE, Jain UR, Levitan RD. Open trial of light therapy in adult attention-deficit/hyperactivity disorder. Oct 1527–1535
Rynn M see Brawman-Mintzer O; Rickels K
Rynn MA see Feiger AD
Rytsälä HJ see Mantere O
Sachs GS. Implementing evidence-based treatment of manic and mixed episodes. Suppl 11, 12–17
Sachs GS. Review of agitation in mental illness: burden of illness and underlying pathology. Suppl 10, 5–12
Sachs GS see Bauer MS; Joffe H; Nierenberg AA; Ostacher MJ; Pollack MH; Reilly-Harrington N
Sackeim HA see Trivedi MH
Safren SA. Cognitive-behavioral approaches to ADHD treatment in adulthood. Suppl 8, 46–50
Sageman S, Brown RP. 3-acetyl-7-oxo-dehydroepiandrosterone for healing treatment-resistant posttraumatic stress disorder in women: 5 case reports [letter]. Mar 493–495
Saha TD see Grant BF; Huang B
Saikali KG see Kornstein SG
Saiz-Ruiz J see Baca-García E
Sajatovic M, Kales HC. Diagnosis and management of bipolar disorder with comorbid anxiety in the elderly. Suppl 1, 21–27
Sajatovic M see Gianfrancesco FD
Salomon RM. Review of Kandel ER: *Psychiatry, Psychoanalysis, and the New Biology of the Mind.* Jan 168
Saltarelli M see Bowden CL
Salzman C. Review of Perry PJ, Alexander C, Liskow BI, DeVane CL: *Psychotropic Drug Handbook, 8th ed.* Dec 2035–2036
Salzman C. Review of Schatzberg AF, Cole JO, Debattista CDMH: *Manual of Clinical Psychopharmacology, 5th ed.* Apr 678
Samet S see Nunes EV
Sanchez R see Keck PE Jr
Sanchez-Moreno J see Vieta E
Santiago-Mozos R see Baca-García E
Santin AP see Fonseca M
Sar V, Akyuz G, Kugu N, Ozturk E, Ertem-Vehid H. Axis I dissociative disorder comorbidity in borderline personality disorder and reports of childhood trauma. Oct 1583–1590
Saria A see Klier CM
Sasson Y see Karamustafalioglu OK
Savas HA see Yumru M
Saxena K see Connor DF
Scalia MJ see Fava M
Schacht A see Lambert M
Schäfer MR see Klier CM
Schaffer A, Cairney J, Cheung AH, Veldhuizen S, Levitt AJ. Use of treatment services and pharmacotherapy for bipolar disorder in a general population–based mental health survey. Mar 386–393
Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. Suppl 4, 27–30
Schecter JM see Carpenter LL
Scheen A see De Hert M; van Winkel R
Schene AH see Bockting CLH; Ruhé HG
Schimmelmann BG see Lambert M
Schmid P see Steinert T
Schmid-Siegel B see Klier CM
Schneck CD. Treatment of rapid-cycling bipolar disorder. Suppl 11, 22–27
Schneider F see Driessen M
Schnyer RN see Allen JJB
Schoenfeld DA see Henderson DC
Schooler NR. Relapse prevention and recovery in the treatment of schizophrenia. Suppl 5, 19–23
Schooler NR see Weissman EM
Schroeder T see Driessen M
Schuh LM see Perlis RH
Schwarzman LK see Chengappa KNR
Schwertfeger N see Wolf J
Scott JA see Thompson WK
Sedillo A see Swanson JM
Séguin M see McGirr A
Seidman SN see Fava M
Selek S see Yumru M
Selzer J. Buprenorphine: reflections of an addictions psychiatrist [ASCP Corner]. Sept 1466–1467
Senturk V, Bilgic A, Atbasoglu EC. Case of probable bipolar VI disorder? [letter]. Aug 1309–1310
Serra M see Plana MT
Shakir S see Djulus J
Shalev AY see Weiniger CF
Shear MK see Blank S; Szanto K; Ursano RJ
Shelton RC. Nature of the discontinuation syndrome associated with antidepressant drugs. Suppl 4, 3–7
Shelton RC, Haman KL, Rapaport MH, Kiev A, Smith WT, Hirschfeld RMA, Lydiard RB, Zajecka JM, Dunner DL. Randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. Nov 1674–1681

Shelton RC see Schatzberg AF; Trivedi MH
Shillcutt SD see Carter WG III
Shim J-C see Jung D-U
Shin D see Ha JH
Shin J-G see Jung D-U
Shin YC see Kwon JS
Shireman TI see Moeller KE
Silander HC see Merrill CA
Silowash R see Szanto K
Simon GE, Khandker RK, Ichikawa L, Operskalski BH. Recovery from depression predicts lower health services costs. Aug 1226–1231
Simon NM, Hoge EA, Fischmann D, Worthington JJ III, Christian KM, Kinrys G, Pollack MH. Open-label trial of risperidone augmentation for refractory anxiety disorders. Mar 381–385
Simon NM see Pollack MH
Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, Rodriguez S, Gharabawi GM. 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. Aug 1194–1200
Simpson HB, Huppert JD, Petkova E, Foa EB, Liebowitz MR. Response versus remission in obsessive-compulsive disorder. Feb 269–276
Simpson HB see Blanco C
Simpson KD see Alessi-Severini S
Singh NM see Andrade C
Siracusano A see Leo R
Sjögren MJC see Merrill CA
Skillecorn A see Ball JR
Sklar P see Finn CT
Sklarsky KG see Papakostas GI
Slaff I. Response to the management of autism and its related disorders [letter]. Dec 2030
Slomowitz M. Review of Stone MH: *Personality-Disordered Patients: Treatable and Untreatable*. Nov 1823
Smeeding JE see Gardner HH
Smith M see Ball JR
Smith S see Grant BF
Smith SM see Huang B
Smith WT see Shelton RC
Smoller JW see Finn CT
Sneed JR see Fogel SP
Soares JC see Fonseca M
Søgaard AJ see Birkenaes AB
Solomon DA, Leon AC, Maser JD, Truman CJ, Coryell W, Endicott J, Teres JJ, Keller MB. Distinguishing bipolar major depression from unipolar major depression with the screening assessment of depression-polarity (SAD-P). Mar 434–442
Solomon DA see Keitner GI
Somasundaram DJ, van de Put WACM. Management of trauma in special populations after a disaster. Suppl 2, 64–73
Somerset WI see Musselman DL
Sood AB see Pilowsky DJ
Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. Suppl 6, 16–22
Souery D see Nutt DJ
Sousa MB, Isolan LR, Oliveira RR, Manfro GG, Cordioli AV. Randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder. July 1133–1139
Soyka M see Brunnauer A
Spencer TJ. ADHD and comorbidity in childhood. Suppl 8, 27–31
Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, Glatt SJ, Biederman J. Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. Mar 415–420
Spencer TJ see Biederman J; Wilens TE
Spier SA. Use of atypical antipsychotics: observations from clinical practice [ASCP Corner]. Mar 490–491
Spigset O see Castberg I
Spinhoven P see Bockting CLH; Greeven A
Stanford/Howard/AACAP Workgroup on Juvenile Impulsivity and Aggression see Connor DF
Stecher VJ see Fava M
Steen VM see Raeder MB
Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? an analysis of placebo-controlled studies of escitalopram. Nov 1741–1746
Stein DJ see Bandelow B; Blanco C; Foa EB; Woods DW
Stein MB. Epidemiologic perspective on social anxiety disorder. Suppl 12, 3–8
Steiner H see Connor DF
Steinert T, Schmid P, Bergbauer G. History of trauma in people with schizophrenia predicts need for seclusion and restraint [letter]. June 995
STEP-BD Investigators see Bauer MS
Stephan DA see Papassotiropoulos A
Sterr A, Padberg F, Amann B, Mergl R, Mulert C, Juckel G, Hegerl U, Pogarell O. Electroencephalographic abnormalities associated with antidepressant treatment: a comparison of mirtazapine, venlafaxine, citalopram, reboxetine, and amitriptyline [letter]. Feb 325–326
Stewart DE see Kornstein SG
Stinson FS see Alegria M; Conway KP; Grant BF; Huang B
Stip E see Mancini-Marïe A
Stolker JJ see Hugenholtz GWK
Stolker JL see Goedhard LE
Stoll AL see Freeman MP
Strain JJ. Review of Treisman GJ, Angelino AF: *The Psychiatry of AIDS: A Guide to Diagnosis and Treatment*. Aug 1312
Strakowski SM see Weinstein SK
Strauss BA see Tepper ML
Strauss R see Laimer M
Strawn JR, Keck PE Jr. Early bicarbonate loading and dantrolene for ziprasidone/haloperidol–induced neuroleptic malignant syndrome [letter]. Apr 677
Strawn JR see Keck PE Jr
Stricker BHCh. Reply to Tepper ML: Methodological concerns regarding the relation between mefloquine and serious psychiatric events in females [letter]. Jan 164–165
Stuart GL see Heru AM
Stunkard AJ, Allison KC, Lundgren JD, Martino NS, Heo M, Etemad B, O'Reardon JP. Paradigm for facilitating pharmacotherapy at a distance: sertraline treatment of the night eating syndrome. Oct 1568–1572
Su K-P see Lin C-Y
Sudak HS. Review of Binder JL: *Key Competencies in Brief Dynamic Psychotherapy: Clinical Practice Beyond the Manual*. May 840
Sundet K see Birkenaes AB
Suominen K see Mantere O
Suppes T see Altshuler LL; Frye MA; Toprac MG
Surman CB see Fried R
Surman CBH, Randall ET, Biederman J. Association between attention-deficit/hyperactivity disorder and bulimia nervosa: analysis of 4 case-control studies. Mar 351–354
Suzuki K see Kaneita Y
Swann AC see Bowden CL
Swanson JM, Greenhill LL, Lopez FA, Sedillo A, Earl CQ, Jiang JG, Biederman J. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. Jan 137–147
Swanson JM see Biederman J
Swanson JW see Ascher-Svanum H
Swartz MS see Ascher-Svanum H
Sweitzer DE see Zhong KX
Swift RM. Introduction: practical pharmacotherapeutic management strategies for patients with alcohol dependence. Suppl 14, 3–5
Swift RM see Bohn MJ
Swinkels JA see Ruhé HG
Szanto K, Shear MK, Houck PR, Reynolds CF III, Frank E, Caroff K, Silowash R. Indirect self-destructive behavior and overt suicidality in patients with complicated grief. Feb 233–239
Taitano EK see Moreno FA
Takahashi H, Kamata M, Yoshida K, Ishigooka J, Higuchi H. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. Oct 1577–1582
Takahashi S see Osone A
Takemura S see Kaneita Y
Talati A see Pilowsky DJ
Tamás Z see Liu X
Tamminga CA. Neurobiology of cognition in schizophrenia. Sept e11
Tamminga CA. Neurobiology of cognition in schizophrenia. Suppl 9, 9–13

Tanguay PE. Review of Bauman ML, Kemper TL (eds): *The Neurobiology of Autism, 2nd ed.* July 1161–1162
Tansella M see Barbui C
Tapp AM, Kennedy A, Peskind ER, Raskind MA. Beneficial effects of prazosin for visual hallucinations associated with chronic cocaine abuse [letter]. Nov 1819–1820
Tariot PN. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies. Suppl 3, 15–22
Tassone F see Bacalman S
Tavares SB see Wier LM
Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: a review. July 1034–1041
Tepper ML, Strauss BA. Methodological concerns regarding the relation between mefloquine and serious psychiatric events in females [letter with reply]. Jan 164–165
Tepper P see Liu X
Teran-Perez G see Prospero-Garcia KA
Teres JJ see Solomon DA
Tesauro M see Leo R
Thase ME. Failure of evidence-based medicine to guide treatment of antidepressant nonresponders [commentary]. Dec 1833–1835
Thase ME. New directions in the treatment of atypical depression. Dec e18
Thase ME. Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression [ASCP Corner]. Apr 671–672
Thase ME see Bauer MS; Gelenberg AJ; Joffe H; Pollack MH
Thompson JW. Primary care pitfalls for the psychiatrist psychopharmacologist [ASCP Corner]. Dec 2026–2027
Thompson TR see Frye MA; Ketter TA
Thompson WK, Kupfer DJ, Fagiolini A, Scott JA, Frank E. Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: analysis of acute-phase data from a randomized controlled trial. May 783–788
Tobias K see Montgomery SA
Toder D see Miodownik C
Tohen M see Brown EB; Cavazzoni PA; Houston JP; Ketter TA; Perlis RH
Tohen MF see Corya SA
Tompson WP see Clancy CP
Tondo L, Albert MJ, Baldessarini RJ. Suicide rates in relation to health care access in the United States: an ecological study. Apr 517–523
Toprac MG, Dennehy EB, Carmody TJ, Crismon ML, Miller AL, Trivedi MH, Suppes T, Rush AJ. Implementation of the Texas Medication Algorithm Project patient and family education program. Sept 1362–1372
Torres-Ruiz A see Prospero-Garcia KA
Tracey B see Blank S
Tragl K-H see Grünblatt E
Tran TB see Ostacher MJ
Tremblay P see Blier P
Trichotillomania Learning Center-Scientific Advisory Board see Woods DW
Trivedi MH. Major depressive disorder: remission of associated symptoms. Suppl 6, 27–32
Trivedi MH, Fava M, Marangell LB, Osser DN, Shelton RC. Use of treatment algorithms for depression [commentary]. Sept 1458–1465
Trivedi MH, Rush AJ, Wisniewski SR, Warden D, McKinney W, Downing M, Berman SR, Farabaugh A, Luther JF, Nierenberg AA, Callan JA, Sackeim HA. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. Feb 185–195
Trivedi MH see Nutt DJ; Pilowsky DJ; Souery D; Toprac MG
Troisi A see Leo R
Truman CJ see Solomon DA
Tsai J-F. Aripiprazole-associated seizure [letter]. June 995–996
Tseng L-J see Fava M
Tsuang J see Mooney LJ
Tummala R see McLaughlin TP
Tümüklü M see Akdede BBK
Tunca Z see Akdede BBK
Turecki G see McGirr A
Turgut TI see Akdede BBK
Turkoz I see Gharabawi GM; Simpson GM
Turner HJ see Emsley R
Tylee A. Identifying and managing depression in primary care in the United Kingdom. Suppl 6, 41–45
Tylee A see Nutt DJ
Tyrka AR see Carpenter LL; Wier LM
Uchiyama M see Kaneita Y
Ulmer HG see Robert S
Urretavizcaya M see Labad J
Ursano RJ, Cerise FP, DeMartino R, Reissman DB, Shear MK. Impact of disasters and their aftermath on mental health [commentary]. Jan 7–14
Vakili N, Gorji A. Psychiatry and psychology in medieval Persia. Dec 1862–1869
Valenstein M, Ganoczy D, McCarthy JF, Kim HM, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. Oct 1542–1550
Valtonen HM see Mantere O
van Balkom AJLM see Greeven A
Van Brunt DL see Phillips GA
van den Broek WW, Birkenhäger TK, Mulder PGH, Bruijn JA, Moleman P. Imipramine is effective in preventing relapse in electroconvulsive therapy–responsive depressed inpatients with prior pharmacotherapy treatment failure: a randomized, placebo-controlled trial. Feb 263–268
van den Broek WW see Birkenhäger TK
van de Put WACM see Somasundaram DJ
Van Eyck D see De Hert M; van Winkel R
van Harten PN, Hoek HW, Matroos GE, van Os J. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao Extrapyramidal Syndromes Study V. Dec 1920–1927
VanMeter SA see Jefferson JW
van Oppen P see Greeven A
van Os J see van Harten PN
van Rood YR see Greeven A
van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. Oct 1493–1500
van Winkel R see De Hert M
Vaskinn A see Birkenaes AB
Vázquez-Barquero JL see Álvarez-Jiménez M; Crespo-Facorro B
Velazquez-Moctezuma J see Prospero-Garcia KA
Veldhuizen S see Schaffer A
Velyvis VP see Goldstein BI
Verger K see Vieta E
Vetró A see Liu X
Vieta E, Goikolea JM, Martínez-Arán A, Comes M, Verger K, Masramon X, Sanchez-Moreno J, Colom F. Double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. Mar 473–477
Vieta E see Plana MT
Vieweg WVR. QTc and metabolic parameters [letter with reply]. May 838–839
Viinamäki HT see Heiskanen TH
Viner MW, Matuszak JM, Knight LJ. Initial dosing strategies for long-acting injectable risperidone [letter]. Aug 1310–1311
Vishne T see Amital D
Vizuete C see De la Fuente JM
Volavka J see Citrome L
Vollset SE see Raeder MB
von Schönfeld C-E see Driessen M
Vornik LA, Brown ES. Management of comorbid bipolar disorder and substance abuse. Suppl 7, 24–30
Vornik LA see Perlis RH
Wagner KD. Bipolar disorder and comorbid anxiety disorders in children and adolescents. Suppl 1, 16–20
Wagner KD, Hirschfeld RMA, Emslie GJ, Findling RL, Gracious BL, Reed ML. Validation of the Mood Disorder Questionnaire for bipolar disorders in adolescents. May 827–830
Wagner M see Pitschel-Walz G
Wagner T see Lambert M
Wainberg ML, Muench F, Morgenstern J, Hollander E, Irwin TW, Parsons JT, Allen A, O'Leary A. Double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. Dec 1968–1973
Walden J see Altshuler LL
Walther MR see Woods DW
Wampers M see De Hert M; van Winkel R
Wang R-h see Gianfrancesco FD
Warczyk S see Damsa C
Warden D see Trivedi MH
Warkentin S see Merrill CA
Wasdell MB see Weiss MD

Waterreus A see Almeida OP
Watkin JG see Kornstein SG; Lewis-Fernández R
Webb R see Kapur N
Weber-Hamann B, Gilles M, Lederbogen F, Heuser I, Deuschle M. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. Dec 1856–1861
Weiden PJ, Young AH, Buckley PF. Art and science of switching antipsychotic medications, part 1. Nov e15
Weiniger CF, Shalev AY, Ofek H, Freedman S, Weissman C, Einav S. Posttraumatic stress disorder among hospital surgical physicians exposed to victims of terror: a prospective, controlled questionnaire survey. June 890–896
Weinstein SK, Adler CM, Strakowski SM. Ziprasidone-induced acute dystonic reactions in patients with bipolar disorder [letter]. Feb 327–328
Weisler RH see Hirschfeld RMA
Weiss M, Hechtman L, The Adult ADHD Research Group. Randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. Apr 611–619
Weiss MD, Gadow K, Wasdell MB. Effectiveness outcomes in attention-deficit/hyperactivity disorder. Suppl 8, 38–45
Weiss RD see Ostacher MJ
Weissman C see Weiniger CF
Weissman EM, Zhu CW, Schooler NR, Goetz RR, Essock SM. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. Sept 1323–1326
Weissman MM see Pilowsky DJ
Welge JA see McElroy SL; Perlis RH
Wenk GL. Neuropathologic changes in Alzheimer's disease: potential targets for treatment. Suppl 3, 3–7
White MA, Grilo CM. Psychiatric comorbidity in binge-eating disorder as a function of smoking history. Apr 594–599
White MA, Masheb RM, Rothschild BS, Burke-Martindale CH, Grilo CM. Prognostic significance of regular binge eating in extremely obese gastric bypass patients: 12-month postoperative outcomes. Dec 1928–1935
Whitley J see Wilens TE
Wickramaratne PJ see Pilowsky DJ
Widmann B see Driessen M
Wiegand CB see Moreno FA
Wier LM, Tavares SB, Tyrka AR, Price LH, Carpenter LL. Levetiracetam-induced depression in a healthy adult. July 1159–1160
Wigal SB see Biederman J
Wightman DS see Clayton AH; Jefferson JW
Wildes JE, Marcus MD, Fagiolini A. Obesity in patients with bipolar disorder: a biopsychosocial-behavioral model. June 904–915
Wilens TE. Mechanism of action of agents used in attention-deficit/hyperactivity disorder. Suppl 8, 32–37
Wilens TE, Zusman RM, Hammerness PG, Podolski A, Whitley J, Spencer TJ, Gignac M, Biederman J. Open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension. May 696–702
Wilkins JN. Traditional pharmacotherapy of alcohol dependence. Suppl 14, 14–22
Williams A see Adetunji B
Williams VSL, Baldwin DS, Hogue SL, Fehnel SE, Hollis KA, Edin HM. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. Feb 204–210
Williamson DJ see Brown EB; Corya SA; Ketter TA
Wilton L see Djulus J
Wingard P see Dunner DL
Winkelman JW. Efficacy and tolerability of open-label topiramate in the treatment of sleep-related eating disorder: a retrospective case series. Nov 1729–1734
Wisner KL see Freeman MP
Wisniewski SR see Bauer MS; Pilowsky DJ; Trivedi MH
Wohlreich MM see Kornstein SG; Lewis-Fernández R
Wolf J, Fiedler U, Anghelescu I, Schwertfeger N. Manic switch in a patient with treatment-resistant bipolar depression treated with modafinil [letter]. Nov 1817
Woodard S see Dunner DL
Woods DW, Flessner CA, Franklin ME, Keuthen NJ, Goodwin RD, Stein DJ, Walther MR, and the Trichotillomania Learning Center-Scientific Advisory Board. Trichotillomania Impact Project (TIP): exploring phenomenology, functional impairment, and treatment utilization. Dec 1877–1888
Worthington JJ III see Simon NM
Wouters LF see Bockting CLH
Wozniak PJ see Bowden CL
Wu P-L see Lin C-Y
Wygant LE see Kinrys G
Wynn JD. Review of Eaton WW (ed): *Medical and Psychiatric Comorbidity Over the Course of Life*. Sept 1475
Xiang J see Chengappa KNR
Xu W see Phillips GA
Yaari R see Caselli RJ
Yaeger D see Charuvastra A
Yağcıoğlu AEA see Akdede BBK
Yager J. Review of Sadler JZ: *Values and Psychiatric Diagnosis*. July 1161
Yatham LN see Frye MA
Yazıcı MK see Akdede BBK
Yokoyama E see Kaneita Y
Yoo HJ see Ha JH
Yoon S-H see Jung D-U
Yoshida K see Takahashi H
Young AH see Mackin P; Weiden PJ
Young CA see Kryzhanovskaya LA
Young D see Zimmerman M
Yumru M, Özen ME, Savas HA, Selek S. Long-acting injectable risperidone for control of agitation in dementia [letter]. Oct 1651–1652
Zablotsky B see Manwani SG
Zajecka JM see Ninan PT; Shelton RC
Zanasi M see Leo R
Zapata R see Lopez-Garcia P
Zarate CA Jr see Perlis RH
Zehetmayer S see Grünblatt E
Zernig G see Klier CM
Zhang H see Henderson DC
Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. July 1093–1103
Zhu B see Ascher-Svanum H
Zhu CW see Weissman EM
Zimbroff DL see Feiger AD
Zimmerman M, Ruggero CJ, Chelminski I, Young D, Posternak MA, Friedman M, Boerescu D, Attiullah N. Developing brief scales for use in clinical practice: the reliability and validity of single-item self-report measures of depression symptom severity, psychosocial impairment due to depression, and quality of life. Oct 1536–1541
Zink M, Knopf U, Argiriou S, Kuwilsky A. Case of pulmonary thromboembolism and rhabdomyolysis during therapy with mirtazapine and risperidone [letter]. May 835
Zohar J see Karamustafalioglu OK
Zornberg GL see Montgomery SA
Zowe M see Langguth B
Zusman RM see Wilens TE

visit *The Journal of Clinical Psychiatry* @
www.psychiatrist.com